View Generic ICR - OIRA Conclusion



0910-0677 201703-0910-009
Historical Active 201604-0910-008
HHS/FDA CDER
Focus Groups About Drug Products As Used by The Food and Drug Administration
Extension without change of a currently approved collection   No
Regular
Approved without change 05/18/2017
Retrieve Notice of Action (NOA) 03/15/2017
This generic clearance for FDA/CDER focus groups is approved for 3-years under the following conditions: (1) For individual focus groups, FDA shall submit a generic IC in ROCIS along with: (a) an abbreviated supporting statement in the template agreed to by OMB and FDA (including a statement of need, intended use of information, description of respondents, date(s) and location(s), collection procedures, number of focus groups, justification for any proposed incentive, and estimated burden); (b) the participant screener, and (c) moderator guide. (2) OMB will respond with clearance or questions within 10 working days.
  Inventory as of this Action Requested Previously Approved
05/31/2020 36 Months From Approved 05/31/2017
1,440 0 1,440
2,520 0 2,520
0 0 0